JP2006306813A - 肥満細胞増殖抑制剤 - Google Patents
肥満細胞増殖抑制剤 Download PDFInfo
- Publication number
- JP2006306813A JP2006306813A JP2005133271A JP2005133271A JP2006306813A JP 2006306813 A JP2006306813 A JP 2006306813A JP 2005133271 A JP2005133271 A JP 2005133271A JP 2005133271 A JP2005133271 A JP 2005133271A JP 2006306813 A JP2006306813 A JP 2006306813A
- Authority
- JP
- Japan
- Prior art keywords
- dgla
- composition according
- mast cells
- composition
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003630 histaminocyte Anatomy 0.000 title claims abstract description 57
- 239000003112 inhibitor Substances 0.000 title description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract description 49
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 10
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 16
- 201000004624 Dermatitis Diseases 0.000 claims description 13
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 7
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 6
- 201000010105 allergic rhinitis Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 208000017520 skin disease Diseases 0.000 claims description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 210000002469 basement membrane Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003921 oil Substances 0.000 description 15
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000007815 allergy Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 150000002617 leukotrienes Chemical class 0.000 description 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- -1 diglyceride Chemical compound 0.000 description 4
- 235000004626 essential fatty acids Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 241000235575 Mortierella Species 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000233639 Pythium Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005133271A JP2006306813A (ja) | 2005-04-28 | 2005-04-28 | 肥満細胞増殖抑制剤 |
| EP19183855.6A EP3581178B1 (en) | 2005-02-14 | 2006-02-10 | Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient |
| EP06713928.7A EP1852114B1 (en) | 2005-02-14 | 2006-02-10 | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
| PCT/JP2006/302787 WO2006085687A1 (ja) | 2005-02-14 | 2006-02-10 | ジホモ−γ−リノレン酸（ＤＧＬＡ）を有効成分として含んで成る組成物 |
| CA2599112A CA2599112C (en) | 2005-02-14 | 2006-02-10 | Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient |
| US11/884,199 US9006287B2 (en) | 2005-02-14 | 2006-02-10 | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| CN 200610003112 CN101019853B (zh) | 2005-02-14 | 2006-02-14 | 含有有效成分二均-γ-亚麻酸(DGLA)的组成物 |
| CN2012100164426A CN102600174A (zh) | 2005-02-14 | 2006-02-14 | 含有有效成分二均-γ-亚麻酸(DGLA)的组成物 |
| US14/644,231 US9943495B2 (en) | 2005-02-14 | 2015-03-11 | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| US15/911,806 US10342773B2 (en) | 2005-02-14 | 2018-03-05 | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005133271A JP2006306813A (ja) | 2005-04-28 | 2005-04-28 | 肥満細胞増殖抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006306813A true JP2006306813A (ja) | 2006-11-09 |
| JP2006306813A5 JP2006306813A5 (https=) | 2008-03-27 |
Family
ID=37474110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005133271A Pending JP2006306813A (ja) | 2005-02-14 | 2005-04-28 | 肥満細胞増殖抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006306813A (https=) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006306812A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
| WO2008111384A1 (ja) | 2007-03-13 | 2008-09-18 | Haruzo Kobayashi | 上皮改善剤 |
| JPWO2010119873A1 (ja) * | 2009-04-13 | 2012-10-22 | 株式会社 資生堂 | 皮下脂肪増加抑制による皮膚の弾性特性の低下の防止方法 |
| US9006287B2 (en) | 2005-02-14 | 2015-04-14 | Suntory Holdings Limited | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| WO2021065659A1 (ja) | 2019-10-01 | 2021-04-08 | サントリーホールディングス株式会社 | アクアポリン３の発現調節を介した腸機能改善用組成物及びその使用 |
| WO2024106446A1 (ja) | 2022-11-15 | 2024-05-23 | 株式会社ニッスイ | アレルギー性鼻炎またはアレルギー性結膜炎の症状の軽減または予防用組成物 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59152324A (ja) * | 1983-02-01 | 1984-08-31 | エフア−モル・リミテツド | 医薬または健康食品組成物 |
| JPH02149508A (ja) * | 1988-03-22 | 1990-06-08 | Efamol Ltd | 皮膚改善用組成物とその方法 |
| JPH04244023A (ja) * | 1991-01-29 | 1992-09-01 | Idemitsu Petrochem Co Ltd | ω６系不飽和脂肪酸含有薬剤 |
| JPH06128154A (ja) * | 1978-01-23 | 1994-05-10 | Efamol Ltd | 食品組成物 |
| JPH06197735A (ja) * | 1979-05-18 | 1994-07-19 | Efamol Ltd | 食品組成物 |
| JP2002047176A (ja) * | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| JP2006219454A (ja) * | 2005-02-14 | 2006-08-24 | Suntory Ltd | 皮膚疾患経口治療または予防剤 |
| JP2006306812A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
-
2005
- 2005-04-28 JP JP2005133271A patent/JP2006306813A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128154A (ja) * | 1978-01-23 | 1994-05-10 | Efamol Ltd | 食品組成物 |
| JPH06197735A (ja) * | 1979-05-18 | 1994-07-19 | Efamol Ltd | 食品組成物 |
| JPS59152324A (ja) * | 1983-02-01 | 1984-08-31 | エフア−モル・リミテツド | 医薬または健康食品組成物 |
| JPH02149508A (ja) * | 1988-03-22 | 1990-06-08 | Efamol Ltd | 皮膚改善用組成物とその方法 |
| JPH04244023A (ja) * | 1991-01-29 | 1992-09-01 | Idemitsu Petrochem Co Ltd | ω６系不飽和脂肪酸含有薬剤 |
| JP2002047176A (ja) * | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| JP2006219454A (ja) * | 2005-02-14 | 2006-08-24 | Suntory Ltd | 皮膚疾患経口治療または予防剤 |
| JP2006306812A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006287B2 (en) | 2005-02-14 | 2015-04-14 | Suntory Holdings Limited | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| US9943495B2 (en) | 2005-02-14 | 2018-04-17 | Suntory Holdings Limited | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| US10342773B2 (en) | 2005-02-14 | 2019-07-09 | Suntory Holdings Limited | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| JP2006306812A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 好酸球浸潤抑制剤 |
| WO2008111384A1 (ja) | 2007-03-13 | 2008-09-18 | Haruzo Kobayashi | 上皮改善剤 |
| US8529879B2 (en) | 2007-03-13 | 2013-09-10 | Haruzo Kobayashi | Epithelium-improving agent |
| JPWO2010119873A1 (ja) * | 2009-04-13 | 2012-10-22 | 株式会社 資生堂 | 皮下脂肪増加抑制による皮膚の弾性特性の低下の防止方法 |
| WO2021065659A1 (ja) | 2019-10-01 | 2021-04-08 | サントリーホールディングス株式会社 | アクアポリン３の発現調節を介した腸機能改善用組成物及びその使用 |
| CN114585355A (zh) * | 2019-10-01 | 2022-06-03 | 三得利控股株式会社 | 借由水通道蛋白3的表达调节的肠功能改善用组合物及其应用 |
| WO2024106446A1 (ja) | 2022-11-15 | 2024-05-23 | 株式会社ニッスイ | アレルギー性鼻炎またはアレルギー性結膜炎の症状の軽減または予防用組成物 |
| EP4620465A1 (en) | 2022-11-15 | 2025-09-24 | Nissui Corporation | Composition for relieving or preventing symptoms of allergic rhinitis or allergic conjunctivitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10342773B2 (en) | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient | |
| EP1430783B1 (en) | Oil/fat composition | |
| CN101019853B (zh) | 含有有效成分二均-γ-亚麻酸(DGLA)的组成物 | |
| Markworth et al. | Arachidonic acid supplementation modulates blood and skeletal muscle lipid profile with no effect on basal inflammation in resistance exercise trained men | |
| CN101072509A (zh) | 炎症的治疗和预防 | |
| JPWO2003074043A1 (ja) | 体温上昇剤 | |
| EP2682116A1 (en) | Metabolic syndrome ameliorating agent | |
| JP2006306813A (ja) | 肥満細胞増殖抑制剤 | |
| JP2006306812A (ja) | 好酸球浸潤抑制剤 | |
| JP2002302441A (ja) | 月経前症候群症状緩和用組成物及び飲食物 | |
| JP6203320B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| JP2012082226A (ja) | 皮膚疾患経口治療または予防剤 | |
| JP7422160B2 (ja) | アクアポリン３の発現調節を介した腸機能改善用組成物及びその使用 | |
| JP6462790B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| JP6214474B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| JP5479696B2 (ja) | 生体内のプラスマローゲン増加剤 | |
| CN120187420A (zh) | 用于减轻或预防过敏性鼻炎或过敏性结膜炎的症状的组合物 | |
| JP2024051305A (ja) | 糖質燃焼促進剤 | |
| HK40075032A (en) | Composition for improving intestinal function through expression control of aquaporin 3, and use thereof | |
| WO2008153220A1 (ja) | 血管疾患の予防又は治療剤 | |
| CN107970232A (zh) | 含n-3系不饱和脂肪酸的组合物、及n-3系不饱和脂肪酸在该组合物的制造中的应用 | |
| JP2018168139A (ja) | ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080213 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120124 |